{"schema_version":"1","generated_at":"2026-10-28T20:01:44.452Z","data_as_of":null,"url":"https://www.findmykol.com/kol/yull-arriaga","json_url":"https://www.findmykol.com/kol/yull-arriaga/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"yull-arriaga","name":"Yull Arriaga","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"St. Luke's University Health Network","institution_url":"https://www.findmykol.com/institution/st-luke-s-university-health-network","city":"Bethlehem","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1023065091","orcid":"0000-0002-7229-2028","openalex":"A5063056787"},"summary":"Yull Arriaga is an Oncology physician affiliated with St. Luke's University Health Network. OpenAlex indexes 130 publications with 2,431 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":130,"cited_by_count":2431,"h_index":20,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00867126","title":"Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine","phase":"EARLY_PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"University of Texas Southwestern Medical Center","source_url":"https://clinicaltrials.gov/study/NCT00867126","trial_url":"https://www.findmykol.com/trial/NCT00867126"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"Novocure Inc.","program_year":2025,"amount_usd":115.56,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023065091"},{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":93.27,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023065091"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":33.64,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023065091"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1023065091","source":"payments"},"prescribing":{"data_year":2019,"areas_total":1,"areas_shown":1,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":100,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":100,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab","year":2024,"journal":"npj Precision Oncology","source_url":"https://doi.org/10.1038/s41698-024-00641-7","status":"verified"},{"title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.00172","status":"verified"},{"title":"Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer","year":2022,"journal":"Biomedicines","source_url":"https://doi.org/10.3390/biomedicines10061419","status":"verified"},{"title":"1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial","year":2022,"source_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1473","status":"verified"},{"title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(21)00152-2","status":"verified"}],"source":"works"},"contact":{"address_1":"801 OSTRUM ST","city":"Bethlehem","state":"PA","zip":"180151000","phone":"484-503-4673","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1023065091","source":"identity"},"similar":[{"name":"Hajime Tokuno","slug":"hajime-tokuno","institution":"St. Luke's University Health Network","specialty":"Neurology","url":"https://www.findmykol.com/kol/hajime-tokuno","json_url":"https://www.findmykol.com/kol/hajime-tokuno/profile.json"},{"name":"Michael Firstenberg","slug":"michael-firstenberg","institution":"St. Luke's University Health Network","specialty":"Thoracic Surgery (Cardiothoracic Vascular Surgery)","url":"https://www.findmykol.com/kol/michael-firstenberg","json_url":"https://www.findmykol.com/kol/michael-firstenberg/profile.json"},{"name":"William Burfeind","slug":"william-burfeind","institution":"St. Luke's University Health Network","specialty":"Thoracic Surgery (Cardiothoracic Vascular Surgery)","url":"https://www.findmykol.com/kol/william-burfeind","json_url":"https://www.findmykol.com/kol/william-burfeind/profile.json"},{"name":"Maher El Chaar","slug":"maher-el-chaar","institution":"St. Luke's University Health Network","specialty":"Surgery","url":"https://www.findmykol.com/kol/maher-el-chaar","json_url":"https://www.findmykol.com/kol/maher-el-chaar/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-03-05","provider_certified":"2025-03-05","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2019}},"methodology_url":"https://www.findmykol.com/about#methodology"}